> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Ovide Not Withdrawn Due to Safety/Efficacy: FDA
- URL: https://www.fdaweb.com/ovide-not-withdrawn-due-to-safety-efficacy-fda/
- Published: 2021-05-14T12:00:00.000Z
- Updated: 2026-09-14T16:59:03.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5149322

*Federal Register* notice: FDA has determined that Taro Pharmaceutical Industries’ Ovide (malathion) lotion, 0.5%, was not withdrawn due to safety or effectiveness reasons. The determination allows FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements. Ovide is indicated for treating patients infected with head lice and their ova. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-05-14/pdf/2021-10166.pdf?ref=fdaweb.com).